The company has substantially boosted its course of the new treatment for cardiac amyloidosis, employing the investigational drug. Initial clinical data indicates promising improvements for those suffering by this https://attrcm350996.blogrelation.com/48792675/bridgebio-improves-amyloidosis-treatment-using-the-therapy